Advertisement Leonardo, NMA ink deal for production of nanoparticles - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Leonardo, NMA ink deal for production of nanoparticles

Drug delivery companies, Leonardo Biosystems and NanoMedical Systems (NMS ) have signed a development contract in which NMS will develop and set up a commercial process to manufacture nanoporous silicon particles for Leonardo's multi-stage drug delivery system.

Leonardo technology comprises fully biodegradable, porous silicon particles that can be loaded with a diverse array of secondary nanoparticles such as liposomes, micelles, carbon nanotubes, dendrimers and metallic nanoparticles.

Leonardo has formed prototype particles, demonstrating all the necessary unit processes to make the particles.

Under the terms of the agreement, NMS will engineer, refine, and integrate these steps in a manner that prepares Leonardo for manufacturing particles suitable for clinical trials.

NanoMedical Systems president and CEO Randy Goodall said their expertise in the development of drug delivery products would support Leonardo in bringing their manufacturing process to a commercial performance level.